Inogen’s (INGN) Hold Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Inogen (NASDAQ:INGN) in a research report sent to investors on Friday morning,Benzinga reports.

Separately, StockNews.com raised Inogen from a “sell” rating to a “hold” rating in a research report on Tuesday, August 13th.

Inogen Price Performance

Shares of NASDAQ INGN opened at $11.02 on Friday. The business’s 50-day moving average price is $9.95 and its two-hundred day moving average price is $9.43. Inogen has a one year low of $4.68 and a one year high of $13.33. The company has a market capitalization of $261.39 million, a P/E ratio of -4.90 and a beta of 1.04.

Hedge Funds Weigh In On Inogen

Several large investors have recently made changes to their positions in INGN. Divisadero Street Capital Management LP lifted its position in shares of Inogen by 682.3% during the 2nd quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company’s stock worth $19,079,000 after purchasing an additional 2,046,766 shares during the last quarter. Brown Capital Management LLC lifted its position in shares of Inogen by 26.6% during the 1st quarter. Brown Capital Management LLC now owns 1,975,312 shares of the medical technology company’s stock worth $15,941,000 after purchasing an additional 414,903 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Inogen by 312.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock worth $1,694,000 after purchasing an additional 132,287 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Inogen by 29.3% during the 2nd quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company’s stock worth $4,642,000 after purchasing an additional 129,307 shares during the last quarter. Finally, Sanctuary Advisors LLC acquired a new position in shares of Inogen during the 2nd quarter worth about $651,000. Institutional investors and hedge funds own 89.94% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.